Second Sight Medical Products, Inc. (EYES): Price and Financial Metrics
GET POWR RATINGS... FREE!
EYES Stock Summary
- For EYES, its debt to operating expenses ratio is greater than that reported by only 0.46% of US equities we're observing.
- With a year-over-year growth in debt of -100%, Second Sight Medical Products Inc's debt growth rate surpasses merely 0% of about US stocks.
- The volatility of Second Sight Medical Products Inc's share price is greater than that of 99.68% US stocks with at least 200 days of trading history.
- Stocks with similar financial metrics, market capitalization, and price volatility to Second Sight Medical Products Inc are SEAC, AEIS, ASTC, GEOS, and ITRI.
- EYES's SEC filings can be seen here. And to visit Second Sight Medical Products Inc's official web site, go to www.secondsight.com.
EYES Stock Price Chart Interactive Chart >
EYES Price/Volume Stats
|Current price||$6.65||52-week high||$20.00|
|Prev. close||$6.28||52-week low||$0.69|
|Day high||$6.84||Avg. volume||16,356,679|
|50-day MA||$6.56||Dividend yield||N/A|
|200-day MA||$3.64||Market Cap||185.59M|
Second Sight Medical Products, Inc. (EYES) Company Bio
Second Sight Medical Products develops, manufactures, and markets implantable prosthetic devices to restore functional vision to blind patients in the United States, Canada, Europe, and Saudi Arabia. The company was founded in 1998 and is based in Sylmar, California.
EYES Latest News Stream
|Loading, please wait...|
EYES Latest Social Stream
View Full EYES Social Stream
Latest EYES News From Around the Web
Below are the latest news stories about Second Sight Medical Products Inc that investors may wish to consider to help them evaluate EYES as an investment opportunity.
Photo by Selman Keles/iStock via Getty Images eyesSecond Sight Medical ([[EYES]] +23.0%) is soaring in morning hours despite a lawsuit filed against the company in France. In a regulatory filing, the company disclosed that on June 01, it received a summons from Pixium Vision in connection with a lawsuit filed in the...
Second Sight Medical Products, Inc. (NASDAQ: EYES) (the "Company" or "Second Sight"), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced results of its annual meeting held May 28, 2021.
Companies in the news are: TM, LHDX, EYES, CVI
Second Sight Medical Products, Inc. (NASDAQ: EYES) (the "Company" or "Second Sight"), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced that the Company received notice from the National Institutes of Health (NIH) of the release of year three funding for its Early Feasibility Clinical Trial of a Visual Cortical Prosthesis (the Orion Trial), grant UH3NS103442. The NIH released $1.4 million of the $6.4 million planned five-year grant. The Company uses the funds primarily to pay UCLA and Baylor College of Medicine to conduct the Orion Trial. This NIH notice of grant award follows the reporting by the Company of promising two-year data from the Orion Trial on May 12, 2021. The funding ...
We're back at it again with a look at the biggest pre-market stock movers for Wednesday and it's clear earnings season is here.
EYES Price Returns
Continue Researching EYESWant to see what other sources are saying about Second Sight Medical Products Inc's financials and stock price? Try the links below:
Second Sight Medical Products Inc (EYES) Stock Price | Nasdaq
Second Sight Medical Products Inc (EYES) Stock Quote, History and News - Yahoo Finance
Second Sight Medical Products Inc (EYES) Stock Price and Basic Information | MarketWatch